Clinical Trial NCT04901936
Trial
Apellis – APL2-PNH-209
Clinical trial ID
NCT04901936
Drug name
APL-2 Pegcetacoplan
Company:
Apellis
Drug trade name
Empaveli® Aspaveli®
Phase of study
2
Current status
Recruiting
Start
02/2021
Substance
Cyclopeptide
Research question
Pediatric
Delivery method of drug
s.c.
Frequency
2 x weekly
Clinical trial locations
Czechia France Malaysia Netherlands Serbia Spain Thainland UK USA